

An AACR Special Conference on

## **Tumor Immunology: Basic and Clinical Advances**

*Presented in conjunction with the Cancer Immunology Working Group of the AACR*

### **Conference Program**

**Tuesday, November 30**

**7:10 p.m.-9:00 p.m. Opening Session**  
***Keynote Addresses***

**Wrestling with melanoma**

David Baltimore

California Institute of Technology, Pasadena, CA

**Malignant progression and the formation of  
cancer stem cells**

Robert A. Weinberg, MIT Whitehead Institute for  
Biomedical Research, Cambridge, MA

**9:00 p.m.-10:30 p.m. Dessert Reception**

**Wednesday, December 1**  
***Tumor Microenvironment***

**8:00 a.m.-10:00 a.m. Session 1:**

**Premalignant Lesions and Prevention**

*Chairperson: Olivera J. Finn, University of Pittsburgh School of Medicine, Pittsburgh, PA*

**TGF- $\beta$ : A master regulator of the tumor microenvironment**

Harold L. Moses, Vanderbilt-Ingram Cancer Center, Nashville, TN

**Conditions for successful immunotherapy of established lesions caused by high-risk human papilloma virus**

Cornelis J.M. Melief, University Hospital Leiden, Leiden, The Netherlands

**Immunoprevention based on tumor-associated antigens**

Olivera J. Finn

**Global approach to tumor immunity: Network signatures of progression and survival\***

Trevor Clancy, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

**Restoration of tumor immune surveillance via selective stimulation of DLL1-Notch signaling\***

Yuhui Huang, Vanderbilt University, Nashville, TN

**10:00 a.m.-10:30 a.m. Break**

**10:30 a.m.-12:30 p.m. Session 2:**

**Antibodies in Cancer Immunity**

*Chairperson: Louis M. Weiner, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC*

**Monoclonal antibody immunotherapy**

Louis M. Weiner

**Antibody fusions with interferon for the treatment of malignancy**

Sherie L. Morrison, University of California, Los Angeles, CA

**Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells\***

Tracy R. Daniels, University of California, Los Angeles, CA

**Optimization of monoclonal antibodies for antitumor efficacy\***

Yong Tang, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

**B lymphocytes inhibit antitumor response in a murine EMT-6 tumor model by facilitating expansion of T regulatory cells\***

Yu Zhang, University of Miami Miller School of Medicine, Miami, FL

**12:30 p.m.-2:30 p.m. Free Time/Lunch on Own**

**2:30 p.m.-4:35 p.m. Session 3:  
Workshop**

*Chairperson: Dmitry I. Gabilovich, H. Lee Moffitt Cancer Center  
and Research Institute, Tampa, FL*

**Characterization of novel huCD16a (FcγRIIIA) transgenic mouse for preclinical  
assessment of therapeutic ADCC-mediating antibodies\***

Christian A. Gerdes, Roche Glycart AG, Zurich, Switzerland

**Adoptive T cell therapy promotes the emergence of genomically altered tumor escape  
variants\***

Karen M. Kaluza, Mayo Clinic, Rochester, MN

**SHP2 regulates pSTAT1-mediated APM component expression and CTL recognition of  
head and neck cancer cells\***

Michael S. Leibowitz, University of Pittsburgh Cancer Institute, Pittsburgh, PA

**Spatial and temporal regulation of CXCR3 chemokine production and CD8 T cell  
infiltration in the metastatic melanoma microenvironment\***

David W. Mullins, University of Virginia, Charlottesville, VA

**Deletion of TGF-β receptor promotes mammary carcinoma progression by enhanced  
Th17 response\***

Sergey Novitskiy, Vanderbilt-Ingram Cancer Center, Nashville, TN

**Regulatory T cells are dependent on PI3K pathway allowing for their selective  
inhibition *in vivo*\***

Raed N. Samara, National Cancer Institute, Bethesda, MD

**The identification of two functionally distinct subsets (Treg and Teff) within the human  
CD4+CD39+ T cell population\***

Patrick J. Schuler, University of Pittsburgh Cancer Institute, Pittsburgh, PA

**Galectin-1 modulates tolerance in neuroblastoma\***

Rocío C. Soldati, Otto-von-Guericke University, Magdeburg, Germany

**4:35 p.m.-6:30 p.m. Poster Session A and Reception**

**Thursday, December 2**

*Harnessing Immune Responses in Cancer*

**8:00 a.m.-10:00 a.m.    Session 4:**

**Combined Therapy**

*Chairperson: Elizabeth M. Jaffee, Johns Hopkins Kimmel  
Comprehensive Cancer Center, Baltimore, MD*

**Functional heterogeneity in CD8+ T cell memory subsets: Implications for immunotherapy**

Stanley Riddell, Fred Hutchison Cancer Research Center, Seattle, WA

**Curing metastatic colon tumors with combined vaccination, radiation, and hematopoietic cell transplantation**

Samuel Strober, Stanford University School of Medicine, Stanford, CA

**Regulatory T cells and their role in the tumor microenvironment**

Elizabeth M. Jaffee

**Vaccination with lymphoma cells secreting gp96-Ig leads to the generation and expansion of CD8 effector cells in autologous HSCT recipients and is enhanced by IL-2 antibody-cytokine complex\***

Robert G. Newman, University of Miami, Miami, FL

**An uncontrolled phase II study of the P53-SLP® vaccine combined with low-dose cyclophosphamide for epithelial ovarian cancer\***

Hans Nijman, University Medical Center Groningen, Groningen, The Netherlands

**10:00 a.m.-10:30 a.m.    Break**

**10:30 a.m.-12:30 p.m. Session 5:**

**Epigenetic Regulation of Tumor Growth and Immune Recognition**

*Chairperson: Eduardo M. Sotomayor, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL*

**Targeting specific histone deacetylases in immune cells and tumor cells to overcome tumor-induced tolerance**

Eduardo M. Sotomayor

**Selective depletion of Foxp3<sup>+</sup> regulatory T cells improves effective therapeutic vaccination against established melanoma**

Jochen Huehn, Helmholtz Centre for Infection Research, Braunschweig, Germany

**Epigenetic targeting of Foxp3<sup>+</sup> Tregs to enhance antitumor immunity**

Wayne W. Hancock, University of Pennsylvania, Philadelphia, PA

**MUC1 regulates interleukins expression in cancer cells\***

Sandra Cascio, University of Pittsburgh, Pittsburgh, PA

**ATF3, a hub of the stress-response network, promotes a systemic host environment that enhances cancer metastasis\***

Tsonwin Hai, The Ohio State University, Columbus, OH

**12:30 p.m.-2:30 p.m. Poster Session B and Lunch**

**2:30 p.m.-4:30 p.m. Session 6:**

**New Advances in the Development of Cancer Vaccines**

*Chairperson: Esteban Celis, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL*

**Reprogramming the immune environment in cancer via dendritic cells**

Anna Karolina Palucka, Baylor University Medical Center, Dallas, TX

**Polarized dendritic cells in cancer therapy: Getting dendritic cells to lymph nodes and effector T cells to tumors**

Pawel Kalinski, University of Pittsburgh, Pittsburgh, PA

**Overcoming obstacles for the development of potent and effective peptide vaccines**

Esteban Celis

**Dual roles of CD91 in heat shock protein-mediated antitumor immunity\***

Robert J. Binder, University of Pittsburgh, Pittsburgh, PA

**Higher avidity mesothelin-specific CD8<sup>+</sup> T cell repertoires are associated with longer disease-free survival and tumor trafficking in patients treated with a GM-CSF-secreting pancreatic tumor vaccine\***

Eric R. Lutz, Johns Hopkins University School of Medicine, Baltimore, MD

**Friday, December 3**

***Regulation of Immune Responses in Cancer***

**8:00 a.m.-10:00 a.m.    Session 7:**  
**Regulation of Immune Responses in Cancer:**  
**A Translational Paradigm**  
*Chairperson: Theresa L. Whiteside, University of Pittsburgh  
Cancer Institute, Hillman Cancer Center, Pittsburgh, PA*

**Human regulatory T cells (Treg) utilize adenosine and PGE<sub>2</sub> to mediate immune suppression**

Theresa L. Whiteside

**Immune monitoring of CTLA-4 blockade on a presurgical clinical trial: Implicating the ICOS/ICOSL pathway in antitumor immune responses**

Padmanee Sharma, University of Texas MD Anderson Cancer Center, Houston, TX

**Blocking PD-1 in advanced cancer**

Charles G. Drake, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

**Molecular characterization of tumor-associated neutrophils\***

Zvi G. Fridlender, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

**NY-ESO-1-specific CD8 T-cell response in NY-ESO-1 seropositive metastatic melanoma patients treated with ipilimumab correlates with clinical benefit\***

Jianda Yuan, Memorial Sloan-Kettering Cancer Center, New York, NY

**10:00 a.m.-10:30 a.m.    Break**

**10:30 a.m.-12:30 p.m. Session 8:  
Harnessing the Immune System to Prevent and  
Fight Disease**

*Chairperson: Cornelis J.M. Melief, University Hospital Leiden,  
Leiden, The Netherlands*

**Next-generation preventive HPV vaccines**

Richard B. Roden, Johns Hopkins University, Baltimore, MD

**Inflammatory cytokines and autocrine tumor-promoting networks**

Frances R. Balkwill, Barts and the London School of Medicine and Dentistry, London, United Kingdom

**Marrow-infiltrating lymphocytes: Role in disease and therapy**

Ivan Borrello, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

**Th-1 lymphocytes promote dendritic cell tumoricidal activity\***

Collin J. LaCasse, University of Arizona, Tucson, AZ

**A new type I NKT cell agonist induces tumor immunity through an unconventional pathway\***

Masaki Terabe, National Cancer Institute, Bethesda, MD

**12:30 p.m.-12:45 p.m. Closing Remarks and Departure**

\*Indicates proffered presentation from selected abstracts.